Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
about
ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA.Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapyCombination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer.
P2860
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Phase II Study of Irinotecan a ...... Unresectable Esophageal Cancer
@ast
Phase II Study of Irinotecan a ...... Unresectable Esophageal Cancer
@en
type
label
Phase II Study of Irinotecan a ...... Unresectable Esophageal Cancer
@ast
Phase II Study of Irinotecan a ...... Unresectable Esophageal Cancer
@en
prefLabel
Phase II Study of Irinotecan a ...... Unresectable Esophageal Cancer
@ast
Phase II Study of Irinotecan a ...... Unresectable Esophageal Cancer
@en
P2093
P2860
P356
P1476
Phase II Study of Irinotecan a ...... Unresectable Esophageal Cancer
@en
P2093
Bhumsuk Keam
Dae Seog Heo
Dong-Wan Kim
Hoon-Gu Kim
Jin-Soo Kim
Jong Seok Lee
Keon Uk Park
Min Kyoung Kim
Seong Hoon Shin
P2860
P304
P356
10.4143/CRT.2016.121
P577
2016-07-28T00:00:00Z